Kaplan Fox Encourages Investors of Hims & Hers Health, Inc. (HIMS) to Contact the Firm to Learn About Their Legal Rights

Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). On July 29, 2026, the Federal Trade Commission ("FTC"), the People of the State of California through Los Angeles County Counsel and the Utah Division of Consumer Protection sued Hims & Hers in the Northern District of California. According to the FTC, the action alleges that Hims & Hers fails to clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is "right for them." The FTC also alleges that the company has made it difficult for consumers to cancel subscriptions and misled consumers about keeping their health information private. The FTC alleges that Hims shared consumers' health information with Meta, Snap and other third parties. Following this news, the price of Hims & Hers stock fell $4.32 per share, or 14.73%, to close at $25.00 per share on July 29, 2026.